GLP-1 Market Key Highlights and Future Opportunities Till 2035
Rise in demand of glp-1 drugs for metabolic disorders. In recent years, owing to its broader clinical potential in the treatment of obesity and type 2 diabetes, along with their proven efficacy in reducing cardiovascular risks, GLP-1 drugs market has garnered significant traction within the medical science domain.
Concurrently, the rising demand and escalating prevalence of metabolic disorder including type 2 diabetes and obesity are fueling the need for treatments capable of effectively managing these conditions. This trend is expected to drive innovation and stimulate market growth within this sector.
The global GLP-1 market size is likely to grow from USD 49.3 billion in 2024 to USD 157.5 billion by 2035, growing at a CAGR of 11.1% during the forecast period, till 2035.
Over the years, rise in the demand of GLP-1 drugs has increased the research activity in this domain. The rich pipeline of GLP-1 drugs is also driving growth in the GLP-1 market, as the conditions like obesity is on the rise, more patients and doctors are looking for treatment options. As the market climbs higher, addressing issues of cost and availability will be essential in making sure that the advantages of GLP-1 medications are accessible to a broader group of people. With ongoing research and development, we anticipate further progress in this area, leading to a new period of managing metabolic conditions.
The current market landscape features the presence of more than 150 GLP-1 drug candidates, intended for the treatment of multiple indications, are currently either approved or being investigated by pharmaceutical companies, that are currently available in the market or under different stages of development.
Majority (close to 60%) of the GLP-1 drug candidates are currently being evaluated in clinical stages of development; of these, most of the candidates target metabolic disorders, such as Type 2 diabetes and obesity. Notably, 11% GLP-1 drugs candidates are approved by various regulatory body across the globe.
Further, most (56%) of the GLP-1 drugs are currently being evaluated as a single agonist followed by dual-agonist (32%) and tri-agonist (12%) for the treatment of various metabolic and other disorders; examples of tri-agonist include (in alphabetical order, phase II / phase III studies) DR10624 (Doer Biologics), Efocipegtrutide, HM15211 (Hanmi Pharmaceutical), HM15275 (Hanmi Pharmaceutical), MWN101 (Shanghai Minwei Biotechnology), Retatrutide, LY3437943 (Eli Lilly) and UBT251 (United Bio-Technology)
The GLP-1 market is highly fragmented, featuring the presence of well-established as well as emerging players. The GLP-1 market is currently dominated by the presence of mid-sized companies (27%). This is followed by small (25%) and very large companies (21%).
The latest research report specializes in the in-depth analysis of the macroeconomic and microeconomic factors affecting the GLP-1 Market development. The report also concentrates on the regulatory framework that is shaping the future of the global market. New and existing pricing structures, emerging application areas, and upcoming investment opportunities have also been detailed in the report. The report further studies the projected growth factors that are expected to influence the market dynamics over the forecast timeframe.
The study is inclusive of a comprehensive analysis of the commonly used marketing and promotional strategies adopted by the key market players. Taking into account the existing market development factors, historical events, and recent market trends, the study presents a balanced opinion on the future scenario of the GLP-1 Market. It thus supports its opinion by discussing the key corporate strategies, such as mergers & acquisitions, takeovers, joint ventures, and strategic alliances, used by the market players to strengthen their global footprint.
Research Methodology
Our analysts have performed an accurate examination of the various aspects of the global market leveraging avant-garde primary and secondary sources of data collection. The report has gathered the necessary data and information from several reliable sources. Additionally, the report offers many strategic recommendations for companies involved in this ever-growing business sector to help them attain a competitive edge in the GLP-1 Market.
Thank you for reading our report. Kindly get in touch with us to know more about the report or to receive a customized copy of it. Our team will ensure the report is tailored according to your needs.
To get sample report visit@
https://www.rootsanalysis.com/reports/glp-1-market/request-sample.html
